Antibodies to the C-terminal fragment β-subunit through the mechanisms of allosteric modulation sensitize the insulin receptor, increase its sensitivity to both endogenous and injected insulin, which is accompanied by activation of the metabolism of insulin-dependent glucose. The presence of antibodies to β- a subunit of moderately expressed hypoglycemic effect (decrease in fasting glycemia by 0.7-1.4 mmol / l), while prolonged use was not accompanied by the development of such side effects as hypoglycemia, acidosis, weight gain, hemostasis and hematopoiesis.
Antibodies to endothelial NO synthase increase the activity of endothelial NO synthase, which is accompanied by an increase in the content of NO, which has an endothelioprotective effect, contributes to a decrease in vascular reactivity, a reduction in vascular spasm, normalization of blood pressure, and improvement of peripheral microcirculation.
Antibodies to endothelial NO synthase have a moderate psychotropic effect in the form of anti-anxiety, anti-asthenic, vegetostabilizing effects.
With the joint use of components in the complex preparation "Subetta" a synergistic effect on sensitivity is observed somatic cells to insulin - due to nonspecific NO-dependent activation of intracellular signal transduction from the insulin receptor, which allows increase the effectiveness of insulin therapy, stabilize applied doses and reduce the risk of side effects.
The drug reduces the severity of complications of diabetes: cardiovascular disorders, neuropathies, nephropathies.